Hello, everyone, and how are you today? A bright, shiny sun is enveloping the Pharmalot campus, where the shortest of short people has left for the local schoolhouse, the official mascots are lolling about and we are, as usual, quaffing cups of stimulation. Thankfully, a prescription is not required. Perhaps you can relate. Meanwhile, here are some items of interest to keep things moving along. Have a smashing day and keep us in mind for fascinating tidbits…
A landmark government-funded study finds that schizophrenia patients receiving smaller doses of antipsychotics and more one-on-one talk therapy and family support fare better over the first two years of treatment than patients who got the usual drug treatment; Robert Califf, whose nomination to lead the FDA is under scrutiny for his ties to drug and device makers, previously directed a business that specializes in helping health care companies hire faculty members and other academic researchers to influence regulatory decisions; and prices have been rising for priority review vouchers, which FDA awards developers of drugs for rare pediatric conditions or tropical diseases.
